Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Fig. 5

Intracellular interactions and remote regulations of hypoxia signaling in cardiovascular diseases. a HIF-αs in intercellular lactate shuttle. b HIF-αs in EPO generation. c Relationship between HIF-αs in cardiovascular diseases and adipose tissue. (Created with BioRender.com). Abbreviations: ACER2 alkaline ceramidase 2, ADRB3 β3-Adrenergic receptors, bFGF basic fibroblast growth factor, bFGFR basic fibroblast growth factor receptor, CAIX carbonic anhydrase IX, DCYTB duodenal cytochrome b reductase 1, DMT1 divalent metal transporter 1, ERFE erythroferrone, FPN ferroportin, GLS1 Glutaminase 1, IDH1 Isocitrate Dehydrogenase 1, IL-8 Interleukin-8, IL-8R Interleukin-8 Receptor, Irak-M interleukin-1 receptor-associated kinase M, IRE iron-responsive element, IRP1 iron-regulatory protein 1, M2 M2 macrophage, MPC mitochondrial pyruvate carrier, mTORC1 mechanistic target of rapamycin complex 1, NAD+ nicotinamide adenine dinucleotide, NF-κB nuclear factor-kappa B, NHE1 sodium-hydrogen exchanger 1, Pdgf platelet-derived growth factor, PGC-1α peroxisome proliferator-activated receptor gamma coactivator-1 alpha, pH potential of hydrogen, RBC red blood cell, RXR retinoid × receptor, SLC1A5 Solute Carrier Family 1 Member 5, SMPD sphingomyelin phosphodiesterase, TF transferrin, TFR1 transferrin receptor 1, VEGFR2 vascular endothelial growth factor receptor 2, WAT white adipose tissue

Back to article page